Saturday, 24 Oct 2026

Empowering Chinese Pharma’s Global Expansion

Contact US
Insight,  China's Pharmaceutical Industry
  • Home
  • About US
  • Policy Hub
  • Categories
    • Drug
    • Company
    • Deals
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Legal / IP
    • Digital
  • Privacy Policy
  • Contact US
My News
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
Insight,  China's Pharmaceutical IndustryInsight,  China's Pharmaceutical Industry
  • Read History
Search
  • Pages
    • Home
    • Blog Index
    • POLICY HUB
    • Contact Us
  • Personalized
    • Read History
  • Categories
    • Company
    • Drug
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Digital
    • Legal / IP
    • Deals
Have an existing account? Sign In
Follow US
Merck Secures FDA Approval for Keytruda-Welireg Combination as Adjuvant Therapy in High-Risk Kidney Cancer
CompanyDrug

Merck Secures FDA Approval for Keytruda-Welireg Combination as Adjuvant Therapy in High-Risk Kidney Cancer

June 15, 2026
Policy / Regulatory

China’s NHSA Receives Record 818 Drug Applications for 2026 National Reimbursement Drug List Adjustment

June 15, 2026
CompanyDrug

Simcere Pharmaceutical Secures NMPA Approval for SIM0689 Bispecific Antibody Targeting PD-1 and VEGF in Solid Tumors

June 15, 2026
CompanyDrug

Mabwell Bioscience Secures FDA Approval for 6MW5311 Bispecific Antibody Trial in Hematologic Malignancies

June 15, 2026
Qingfeng Pharmaceutical Group Partners with TASCO PHARMA to Commercialize Anti-Tumor and CNS Medicines in Vietnam
CompanyDeals

Qingfeng Pharmaceutical Group Partners with TASCO PHARMA to Commercialize Anti-Tumor and CNS Medicines in Vietnam

June 15, 2026
Merck Secures NMPA Approval for Enflonsia (Clesrovimab) – First Single-Dose RSV Monoclonal Antibody in China
CompanyDrug

Merck Secures NMPA Approval for Enflonsia (Clesrovimab) – First Single-Dose RSV Monoclonal Antibody in China

June 15, 2026
CompanyDeals

Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal

June 12, 2026
Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC
CompanyDrug

Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC

June 12, 2026
CompanyDrug

Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria

June 12, 2026
Policy / Regulatory

China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added

June 12, 2026
CompanyDrug

Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Deucravacitinib in Phase III Psoriasis Trial with 35% PASI 100 Response Rate

June 12, 2026
CompanyDeals

Kelun-Biotech Receives USD 89 Million Settlement Payment from Medilink Therapeutics Over ADC Pipeline Out-Licensing Dispute

June 12, 2026
1 2 … 9 10 11 12 13 … 24 25
Insight,  China's Pharmaceutical Industry

Information You Can Trust: Stay instantly connected with breaking stories and live updates. From politics and technology to entertainment and beyond, we provide real-time coverage you can rely on, making us your dependable source for 24/7 news.

Youtube Medium Rss

About Company

  • Contact Us
  • Advertise with US
  • Complaint
  • Our Team
  • Our Values
  • Privacy Policy
Subscribe Now for Real-time Updates on the Latest Stories!

© 2026 Fineline Information & Technology. Independent intelligence on China’s pharmaceutical industry.  All Rights Reserved.

Fineline Information & Technology
Welcome to Fineline Cube!
Username or Email Address
Password

Lost your password?

Not a member? Sign Up